Adaptive Biotechnologies Corp. (ADPT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$24.42+0.33%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Adaptive Biotechnologies raised its 2026 revenue guidance to $260-$270 million. The company aims for positive adjusted EBITDA and free cash flow by end of 2026. Recent earnings beats show improving execution. The $345 million convertible notes fund share buybacks, supporting capital allocation.
Adaptive remains loss-making with negative EPS expected through 2027. Operating expenses near $355 million may pressure margins. Debt issuance increases financial risk. Growth may slow below analyst expectations.
The price is about 13% above our fair value near $18. Analysts expect roughly 13% revenue growth. Our view aligns with these expectations but notes elevated risk from losses and debt.
Breaks if: Convertible notes proceeds not used for planned buybacks or debt repayment
Breaks if: operating expenses exceed $360 million or fall below $350 million in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
ADPT represents a growth investment with a focus on expanding its MRD revenue. The current thesis state is intact, supported by recent earnings performance and management's commitment to growth.
The market currently prices ADPT with a low expectations gap, indicating that it is justified in its valuation despite being loss-making. It trades at a premium compared to peers, reflecting a durable premium in its sector.
Management is on track to achieve strong double-digit revenue growth while controlling operating expenses. However, there is a near-term risk of missing expectations, particularly given the high miss rate in the industry.
The thesis hinges on ADPT's ability to maintain revenue growth and manage expenses effectively. Additionally, the performance of sector bellwethers and overall economic conditions will be critical in shaping future outcomes.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings report missed expectations. This miss raises concerns about the company's performance. There are no new strengths to support the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: adjusted EBITDA and free cash flow remain negative through FY26
Breaks if: MRD revenue falls below $260 million in FY26
Increase full year 2026 revenue guidance for the Minimal Residual Disease (MRD) business to reflect growth expectations.
In the next 1-3 years, ADPT's performance will depend on its execution and external market factors. Not investment advice.